BCLI
BRAINSTORM CELL THERAPEUTICS INC.
NASDAQ · Healthcare · Biotechnology · US
$0.77
−1.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.83
From 52W high−46.53%
Volume468.00
Market cap$8.48M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.83
From 52W high
−46.53%
Volume
468.00
Market cap
$8.48M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
41.5
MomentumView details →
1D Return
−1.17%
YTD Return
+47.48%
SummaryUpdated Jun 1, 2026
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) is a biotechnology company founded in 2000 and incorporated in New York. Originally established as Golden Hand Resources Inc., the company changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 and went public in October 2003. The company specializes in developing autologous cellular therapies for neurodegenerative diseases, with its flagship product NurOwn currently in late-stage clinical trials for amyotrophic lateral sclerosis (ALS). Brainstorm has faced significant financial challenges in recent years, operating with minimal cash reserves while pursuing regulatory approval for its lead therapy.
Similar companies
Latest newsMore news →
BrainStorm Cell Therapeutics Inc. announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update on its NurOwn ALS program preparations for the Phase 3b ENDURANCE study.66d agoLunai Bioworks signed a definitive collaboration agreement with BrainStorm Therapeutics, with initial Parkinson's disease data readout targeted for the first half of 2027.76d ago